Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Asperigillus and Candida

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 5, 2004, Pages 743-749

  Warn, Peter A ^a   Sharp, A ^a   Guinea, J ^a   Denning, David W ^a,b  

^a HOPE HOSPITAL   (United Kingdom)

^b WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

Antifungals; Hypoxia; Susceptibility tests

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE; MICAFUNGIN;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; CANDIDA; CONTROLLED STUDY; HYPOXIA; IN VITRO STUDY; INCUBATOR; MEDICAL SOCIETY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OXYGEN TENSION;

AMPHOTERICIN B; ANOXIA; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; ASPERGILLUS; CANDIDA; GASES; ITRACONAZOLE; LIPOPROTEINS; MICROBIAL SENSITIVITY TESTS; OXYGEN; PEPTIDES, CYCLIC;

EID: 2442713966     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh153     Document Type: Article

References (42)

1. Groll, A. H., Shah, P. M., Mentzel, C. et al. (1996). Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. Journal of Infection 33, 23-32.
2. Pfaller, M. A., Jones, R. N., Doern, G. V. et al. (1998). International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group. Journal of Clinical Microbiology 36, 1886-9.
3. Beck-Sague, C. & Jarvis, W. R. (1993). Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. Journal of Infectious Diseases 167, 1247-51.
4. Jarvis, W. R. (1995). Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Journal of Infectious Diseases 20, 1526-30.
5. Denning, D. W. (1996). Therapeutic outcome in invasive aspergillosis. Clinical Infectious Diseases 23, 608-15.
6. Garbino, J., Kolarova, L., Rohner, P. et al. (2002). Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital. Medicine 81, 425-33.
7. Anaissie, E. J., Rex, J. H., Uzun, O. et al. (11998). Predictors of adverse outcome in cancer patients with candidemia. American Journal of Medicine 104, 238-45.
8. National Committee for Clinical Laboratory Standards. (2002). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium-Forming Filamentous Fungi: Approved Standard Document M38-A. NCCLS, Wayne, PA, USA.
9. National Committee for Clinical Laboratory Standards. (2002). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts - Second Edition: Approved Standard Document M27-A2. NCCLS, Wayne, PA, USA.
10. Johnson, E. M., Oakley, K. L., Radford, S. A. et al. (2000). Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. Journal of Antimicrobial Chemotherapy 45, 85-93.
11. Warn, P. A., Morrissey, J., Moore, C. B. et al. (2000). In vivo activity of amphotericin B lipid complex in immunocompromised mice against fluconazole-resistant or fluconazole-susceptible Candida tropicalis. Antimicrobial Agents and Chemotherapy. 44, 2664-71.
12. Pfaller, M. A., Messer, S. A., Mills, K. et al. (2000). In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference microdilution methods for determining itraconazole MICs. Journal of Clinical Microbiology 38, 3359-61.
13. Meletiadis, J., Mouton, J. W., Meis, J. F. et al. (2002). Comparison of the Etest and the Sensititre colorimetric methods with the NCCLS proposed standard for antifungal susceptibility testing of Aspergillus species. Journal of Clinical Microbiology 40, 2876-85.
14. West, J. B. (1985). Respiratory Physiology - The Essentials, 3rd edn. Williams & Wilkins, Baltimore, MD, USA.
15. 2 in drainage fluid allows for rapid detection of infectious complications during the follow-up period after abdominal surgery. Infection 22, 386-9.
16. 2 in abscesses, peritoneal fluid, and drainage fluid in the presence or absence of bacterial infection during and after abdominal surgery. American Journal of Surgery 166, 24-7.
17. Bryant, R. E., Fox, K., Oh, G. et al. (1992). Beta-lactam enhancement of aminoglycoside activity under conditions of reduced pH and oxygen tension that may exist in infected tissues. Journal of Infectious Diseases 165, 676-82.
18. Sokol-Anderson, M. L., Brajtburg, J. & Medoff, G. (1986). Amphotericin B-induced oxidative damage and killing of Candida albicans. Journal of Infectious Diseases 154, 76-83.
19. Gudewicz, T. M., Mader, J. T. & Davis, C. P. (1987). Combined effects of hyperbaric oxygen and antifungal agents on the growth of Candida albicans. Aviation, Space and Environmental Medicine 58, 673-8.
20. Cuenca- Estrella, M., Diaz-Guerra, T. M., Mellado, E. et al. (2001). Influence of glucose supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida spp. Journal of Clinical Microbiology 39, 525-32.
21. Patterson, T. F., Kirkpatrick, W. R., White, M. et al. (2000). Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 79, 250-60.
22. Stevens, D. A., Kan, V. L., Judson, M. A. et al. (2000). Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clinical Infectious Diseases 30, 696-709.
23. Wingard, J. R., Kubilis, P., Lee, L. et al. (1999). Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clinical Infectious Diseases 29, 1402-7.
24. Herbrecht, R., Denning, D. W., Patterson, T. F. et al. (2002). Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. New England Journal of Medicine 347, 408-15.
25. Espinel-Ingroff, A., Barchiesi, F., Hazen, K. C. et al. (1998). Standardization of antifungal susceptibility testing and clinical relevance. Medical Mycology 36, Suppl. 1, 68-78.
26. Espinel-Ingroff, A., Dawson, K., Pfaller, M. et al. (1995). Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrobial Agents and Chemotherapy 39, 314-9.
27. Pfaller, M. A., Grant, C., Morthland, V. et al. (1994). Comparative evaluation of alternative methods for broth dilution susceptibility testing of fluconazole against Candida albicans. Journal of Clinical Microbiology 32, 506-9.
28. Espinel-Ingroff, A., Fothergill, A., Peter, J. et al. (2002). Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS Collaborative Study. Journal of Clinical Microbiology 40, 3204-8.
29. Jessup, C., Reyes, G., Fothergill, A. et al. (2000). A head-on comparison of the in vitro antifungal activity of conventional and lipid-based amphotericin B: a multicenter study. Journal of Chemotherapy 12, 22-9.
30. Mosquera, J., Warn, P. A., Morrissey, J. et al. (2001). Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo. Antimicrobial Agents and Chemotherapy 45, 1456-62.
31. Manavathu, E. K., Alangaden, G. J. & Lerner, S. A. (1996). A comparative study of the broth micro- and macro-dilution techniques for the determination of the in vitro susceptibility of Aspergillus fumigatus. Canadian Journal of Microbiology 42, 960-4.
32. Rodriguez-Tudela, J. L., Berenguer, J., Martinez-Suarez, J. V. et al. (1996). Comparison of a spectrophotometric microdilution method with RPMI-2% glucose with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro susceptibility testing of amphotericin B, flucytosine, and fluconazole against Candida albicans. Antimicrobial Agents and Chemotherapy 40, 1998-2003.
33. Denning, D. W., Radford, S. A., Oakley, K. L. et al. (1997). Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigaturs infection. Journal of Antimicrobial Chemotherapy 40, 401-14.
34. Denning, D. W. & Warn, P. (1999). Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B. Antimicrobial Agents and Chemotherapy 43, 2592-9.
35. Radetsky, M., Wheeler, R. C., Roe, M. H. et al. (1986). Microtiter broth dilution method for yeast susceptibility testing with validation by clinical outcome. Journal of Clinical Microbiology 24, 600-6.
36. Lass-Florl, C., Kofler, G., Kropshofer, G. et al. (1998). In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. Journal of Antimicrobial Chemotherapy 42, 497-502.
37. Pfaller, M. A., Gerarden, T., Yu, M. et al. (1988). Influence of in vitro susceptibility testing conditions on the anti-candidal activity of LY121019. Diagnostic Microbiology and Infectious Disease 11, 1-9.
38. Kurtz, M. B., Abruzzo, G., Flattery, A. et al. (1996). Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infection and Immunity 64, 3244-51.
39. Verweij, P. E., Oakley, K. L., Morrissey, J. et al. (1998). Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrobial Agents and Chemotherapy 42, 873-8.
40. Oakley, K. L., Moore, C. B. & Denning, D. W. (1998). In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrobial Agents and Chemotherapy 42, 2726-30.
41. Kurtz, M. B., Heath, I. B., Marrinan, J. et al. (1994). Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimicrobial Agents and Chemotherapy 38, 1480-9.
42. Inoue, K., Matsuyama, W., Hashiguchi, T. et al. (2001). Expression of vascular endothelial growth factor in pulmonary aspergilloma. Internal Medicine 40, 1195-9.